Page 23 - Multiple Sclerosis Ms News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Spikes in neurofilament light chain levels occur about 1 year before clinical signs of disease worsening in multiple sclerosis, new research suggests.

The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%.

Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.

The central vein sign is an emerging neuroimaging biomarker for multiple sclerosis that may reduce the need for lumbar puncture to detect oligoclonal bands in CSF, a pilot study shows.

High-efficacy therapies for multiple sclerosis have improved disease outcomes for many patients, but physicians are uncertain when to use them.